All Pharma News
price-trendAsk Us
Camurus announces Phase 3 data reinforcing safety and efficacy of CAM2029

Camurus announces Phase 3 data reinforcing safety and efficacy of CAM2029
PR NEWSWIRE
17 Jul 2023
Share Share
Camurus announces FDA approval of Brixadi

Camurus announces FDA approval of Brixadi
PR NEWSWIRE
23 May 2023
Share Share
FDA grants ODD status to Camurus’ CAM2029 to treat polycystic liver disease

FDA grants ODD status to Camurus’ CAM2029 to treat polycystic liver disease
PHARMABIZ
17 Sep 2021
Share Share
Camurus announces PDUFA date for Brixadi

Camurus announces PDUFA date for Brixadi
PR NEWSWIRE
28 Jun 2021
Share Share
Camurus announces Braeburn resubmits New Drug Application for Brixadi in the US

Camurus announces Braeburn resubmits New Drug Application for Brixadi in the US
PRNEWSWIRE
16 Jun 2021
Share Share
Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US

Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the US
PRNEWSWIRE
15 Jun 2021
Share Share
Camurus announces publication showing superior patient treatment satisfaction

Camurus announces publication showing superior patient treatment satisfaction
PRNEWSWIRE
10 May 2021
Share Share
Australian TGA approves key label updates to Buvidal®

Australian TGA approves key label updates to Buvidal®
PRNEWSWIRE
03 May 2021
Share Share
Camurus, Accord, Swedish Orphan Biovitrum (Sobi), Strides Pharma, BI

Camurus, Accord, Swedish Orphan Biovitrum (Sobi), Strides Pharma, BI
PMCPA
03 Mar 2021
Share Share
Camurus Announces Submission of Request for Final Approval of Brixadi™

Camurus Announces Submission of Request for Final Approval of Brixadi™
PRNEWSWIRE
01 Jun 2020
Share Share